SCYX vs AQST โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
AQST Captures Institutional Edge (2โ2 Pillars ยท 6โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Aquestive Therapeutics, Inc. Common Stock (AQST) driven by superior Growth & Margin, Options & Structure while SCYX counters with relative strength in Valuation, Momentum & Technical. Fundamentally, SCYX trades at 1.9x Forward P/E with -126.9% operating margin (-82.8% YoY revenue) versus AQST at N/M Forward P/E and -114.1% operating margin (-41.0% YoY). In options structure, SCYX sits in BREAKDOWN (4th %ile IV; Dealer Gamma Walls on Pro) against AQST sits in BREAKDOWN (64th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | SCYX Revenue | AQST Revenue | SCYX Op. Margin | AQST Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $0M | $70M | -11666.5% | -72.6% | AQST |
| FY2019 | $0M | $50M | -40430.6% | -100.1% | AQST |
| FY2020 | N/A | $50M | N/A | -93.6% | AQST |
| FY2021 | $10M | $50M | -462.2% | -68.2% | AQST |
| FY2022 | $10M | $50M | -1684.5% | -88.2% | AQST |
| FY2023 | $140M | $50M | 51.9% | -29.9% | SCYX |
| FY2024 | $0M | $60M | -990.8% | -53.5% | AQST |
| FY2025 | $20M | $40M | -78.0% | -159.5% | SCYX |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | SCYX | AQST | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $25.9M | $465.7M | Larger Scale | AQST |
| Trailing P/E Ratio Valuation | 1.9x | N/M | Lower Multiple | SCYX |
| Forward P/E Ratio Valuation | 1.9x | N/M | Lower Multiple | SCYX |
| Revenue Growth (YoY) Growth | -82.8% | -41.0% | Higher Growth | AQST |
| Operating Margin (TTM) Profitability | -126.9% | -114.1% | Higher Margin | AQST |
| Net Profit Margin Profitability | -53.5% | -162.3% | Higher Margin | SCYX |
| Return on Equity (ROE) Capital Efficiency | -21.2% | 0.0% | Higher ROE | AQST |
| 52-Week Range Position Momentum | 33% ($1โ$6) | 14% ($3โ$7) | Stronger Trend | SCYX |
| Beta / 30D Volatility Risk Regime | 3.09ฮฒ ยท 73% Vol | 0.89ฮฒ ยท 56% Vol | Lower Realized Risk | AQST |
| Unified Institutional Score Composite Signal | 42.2 / 100 (HOLD) | 62.9 / 100 (BUY) | Higher Composite | AQST |